Evogene Ltd Stock TEL AVIV STOCK EXCHANGE
Equities
IL0011050551
Biotechnology & Medical Research
Sales 2024 * | 17M 6.32B | Sales 2025 * | 31.5M 11.71B | Capitalization | 37.69M 14.01B |
---|---|---|---|---|---|
Net income 2024 * | -20M -7.43B | Net income 2025 * | -17M -6.32B | EV / Sales 2024 * | 2.22 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.2 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
Latest transcript on Evogene Ltd
Managers | Title | Age | Since |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
1st Jan change | Capi. | |
---|---|---|
+26.28% | 48.09B | |
-3.99% | 40.43B | |
+45.32% | 40.62B | |
-6.20% | 28.36B | |
+6.36% | 24.89B | |
-21.47% | 19.01B | |
+27.58% | 12.09B | |
-2.75% | 11.8B | |
-2.02% | 11.88B |